- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03342638
Maximizing Outcome of Multiple Sclerosis Transplantation (MOST)
January 6, 2021 updated by: Richard Burt, MD, Northwestern University
Maximizing Outcome of Multiple Sclerosis Transplantation: "MOST" Trial
Randomized study of autologous un-manipulated peripheral blood hematopoietic stem cell transplant (HSCT) comparing two regimens: (1) cyclophosphamide and rabbit anti-thymoglobulin (rATG) versus (2) cyclophosphamide, rATG, and Intravenous Immunoglobulin (IVIg).
Study Overview
Status
Terminated
Conditions
Detailed Description
Multiple sclerosis (MS) is at onset an immune-mediated demyelinating disease.
In most cases, it starts as a relapsing-remitting disease with distinct attacks and no symptoms between flares.
Over years or decades, virtually all cases transition into a progressive disease in which insidious and slow neurologic deterioration occurs with or without acute flares.
Relapsing-remitting disease is often responsive to immune suppressive or modulating therapies, while immune based therapies are generally ineffective in patients with a progressive clinical course.
This clinical course and response to immune suppression, as well as neuropathology and neuroimaging studies, suggest that disease progression is associated with axonal atrophy.
Disability correlates better with measures of axonal atrophy than immune mediated demyelination.
Therefore, immune based therapies, in order to be effective, need to be started early in the disease course while MS is predominantly an immune-mediated and inflammatory disease.
While current immune based therapies delay disability, no intervention has been proven to prevent progressive disability.The investigators propose a randomized study of autologous unmanipulated peripheral blood hematopoietic stem cell transplant (HSCT) comparing two different conditioning regimens: (1) cyclophosphamide and rabbit anti-thymoglobulin (rATG) versus (2) cyclophosphamide, rATG, and Intravenous Immunoglobulin (IVIg).
Study Type
Interventional
Enrollment (Actual)
66
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 58 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age between 18-58 years
- Diagnosis of MS using revised McDonald criteria of clinically definite MS (Appendix A)
- An EDSS score of 2.0 to 6.0 (Appendix B).
- An EDSS >6.0 may be included if still relapsing-remitting disease and at least two enhancing lesions on MRI within the last three months
- Inflammatory disease despite treatment with standard disease modifying therapy (DMT) including at least 6 months of interferon or Copaxone. Inflammatory disease is defined based on either MRI (gadolinium enhancing lesion, new T2 lesion) or *steroid-treated clinical relapses (prescribed by a neurologist)
Minimum disease activity required:
- Failed a first line DMT (Copaxone or Interferon), defined as two or more *steroid treated clinical relapses within the last 12 months. A clinical relapse may also be evidence of active inflammation on MRI (gadolinium enhancing lesion or new T2 lesion) in the last 12 months on two MRIs at least three months apart
- Failed a second or third line MS Drug: Zinbryta (daclizumab), Aubagio (teriflunomide), Gilenya (fingolimod), Tecifidera (dimethyl fumarate), Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab) or IVIg, defined as one *steroid treated clinical relapse within the last 12 months or evidence of active inflammation on MRI (gadolinium enhancing lesion or new T2 lesion) in the last 12 months.
Cognitive dysfunction that prevents gainful employment, but competent to comply with treatment and informed consent
- A steroid-treated relapse will include a relapse that was severe enough to justify treatment but due to patient intolerance of steroids, they were offered but not used.
Exclusion Criteria:
- Any adult who is unable to consent (for adults who are cognitively impaired due to MS, consent may be obtained from the closest living relative or person who has power of attorney)
- Individuals under the age of 18 or over the age of 58
- Diagnosis of Primary Progressive MS, Secondary Progressive MS, or Clinically Isolated Syndrome (CIS)
- Pregnant women (positive serum or urine human chorionic gonadotropin (HCG) test)
- Women who are breastfeeding
- Prisoners
- Any illness that in the opinion of the investigators would jeopardize the ability of the patient to tolerate aggressive chemotherapy
- Prior history of malignancy except localized basal cell, squamous skin cancer or carcinoma in situ of the cervix
- Any prior chemotherapy or radiation therapy (except for cyclophosphamide used to treat MS disease)
- History of sickle cell disease (SS), SC disease, coagulopathy, or if actively receiving anticoagulation therapy
- History of insulin-dependent diabetes
- Inability or unwillingness to pursue effective means of birth control from the time of evaluation for eligibility until 6 months post-transplant. Effective birth control is defined as (1) abstinence defined as refraining from all acts of vaginal intercourse, (2) consistent use of birth control pills, (3) injectable birth control methods (Depo-provera, Norplant), (4) tubal sterilization or male partner who has undergone vasectomy, (5) placement of an intrauterine device (IUD), or (6) with every act of intercourse, use of diaphragm with contraceptive jelly and/or use of condom with contraceptive foam
- Failure to willingly accept or comprehend irreversible sterility as a side effect of therapy
- Forced expiratory volume at one second (FEV1)/ forced vital capacity (FVC) < 60% of predicted after bronchodilator therapy (if necessary)
- Diffusing capacity of the lungs for carbon monoxide (DLCO) < 60% of predicted
- Resting left ventricular ejection fraction (LVEF) < 50 %
- Bilirubin > 2.0 mg/dl
- Serum creatinine > 2.0 mg/dl
- Known hypersensitivity to mouse, rabbit, or E. Coli derived proteins or to iron compounds/medications
- Presence of metallic objects implanted in the body that would preclude the ability of the patient to safely have MRI exams
- Platelet count < 100,000/ul
- White blood cell count (WBC) < 1,500 cells/mm3
- Psychiatric illness, mental deficiency or cognitive dysfunction making compliance with treatment or informed consent impossible
- Active infection except asymptomatic bacteriuria
- Use of Tysabri (natalizumab) within the previous six months
- Use of Gilenya (fingolimod) within the previous three months
- Use of Tecfidera (dimethyl fumarate) within the previous three months
- Use of Aubagio (teriflunomide) unless cleared from the body (plasma concentration <0.02mcg/ml) following elimination from the body with cholestyramine 8g three times a day for 11 days
- Use of Lemtrada/Campath (alemtuzumab) within previous 12 months
- Use of Rituxan (rituximab) or Ocrevus (ocrelizumab) within previous four months
- Prior treatment with Novantrone (mitoxantrone)
- Any hereditary neurological disease such as Charcot-Marie-Tooth disease (CMT), Spinocerebellar ataxia (SCA), or Parkinson's Disease
- Severe or symptomatic cervical spinal stenosis unless surgically corrected
- Myocardial infarction within last 12 months; if longer than 12 months, must pass dobutamine stress test and be cleared by cardiology
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Control Arm
Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone.
Granulocyte-colony stimulating factor (G-CSF) will be administered post-transplant.
|
Medication used to decrease the risk of hemorrhagic cystitis prophylaxis
Other Names:
A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells
Other Names:
Steroid
Other Names:
Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
Other Names:
Potent immunosuppressive agent; an alkylating agent
Other Names:
Infusion of participant's own stem cells
|
Experimental: IVIg Arm
Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone.
IVIg and G-CSF will be administered post-transplant.
|
Medication used to decrease the risk of hemorrhagic cystitis prophylaxis
Other Names:
A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells
Other Names:
Steroid
Other Names:
Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
Other Names:
Potent immunosuppressive agent; an alkylating agent
Other Names:
Infusion of participant's own stem cells
Sterile, purified immunoglobulin G (IgG) products manufactured from pooled human plasma and typically contain more than 95% unmodified IgG, which has intact Fc-dependent effector functions and only trace amounts of immunoglobulin A (IgA) or immunoglobulin M (IgM).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy - Rate of Disease Activity
Time Frame: 5 years
|
Defined as no relapse (defined as acute neurologic deterioration occurring after engraftment and lasting more than 24 hours, accompanied by objective worsening on neurological examination that are documented by a neurologist and not explained by fever, infection, stress, heat or related pseudoexacerbation; supportive confirmation by enhancement on MRI is preferred), no disease progression (defined as a 1.0-point increase in the Expanded Disability Status Scale (EDSS) on consecutive evaluations at least 6 months apart and not due to a non-MS disease process), and no new or enhancing lesions on MRI
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 8, 2017
Primary Completion (Actual)
July 23, 2019
Study Completion (Actual)
October 9, 2019
Study Registration Dates
First Submitted
November 9, 2017
First Submitted That Met QC Criteria
November 13, 2017
First Posted (Actual)
November 17, 2017
Study Record Updates
Last Update Posted (Actual)
January 11, 2021
Last Update Submitted That Met QC Criteria
January 6, 2021
Last Verified
January 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Multiple Sclerosis
- Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Neuroprotective Agents
- Protective Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Methylprednisolone
- Methylprednisolone Hemisuccinate
- Cyclophosphamide
- Thymoglobulin
Other Study ID Numbers
- DIAD.MOST.2017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis, Relapsing-Remitting
-
BiogenWithdrawnRelapsing-Remitting Multiple Sclerosis | Relapsing Forms of Multiple Sclerosis
-
BiogenWithdrawn
-
BiogenAbbVieTerminatedMultiple Sclerosis | Relapsing-Remitting Multiple SclerosisUnited States, Denmark, Italy, United Kingdom, Czechia, Canada, Hungary, Spain, Australia, Israel, Georgia, Serbia, Russian Federation, Ukraine, India, Poland, Brazil, France, Argentina, Germany, Greece, Ireland, Mexico, Moldova, Republic... and more
-
EMD SeronoPfizerCompletedRelapsing-remitting Multiple SclerosisUnited States, United Kingdom, Argentina, Austria, Brazil, France, Germany, Italy, Netherlands, Russian Federation, Spain, Switzerland
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedRelapsing-Remitting Multiple SclerosisUnited States
-
BiogenTerminatedRelapsing-Remitting Multiple SclerosisUnited States, Spain, Germany, Australia, Sweden, Czechia, France, Italy, United Kingdom
-
Novartis PharmaceuticalsWithdrawnMultiple Sclerosis (Relapsing Remitting)
-
Genzyme, a Sanofi CompanyTerminatedRelapsing-remitting Multiple SclerosisSweden, Poland, Russian Federation, United States, Canada
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple SclerosisGermany
-
Mitsubishi Tanabe Pharma CorporationCompletedRelapsing-remitting Multiple SclerosisCroatia, Bulgaria, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Germany, Lithuania, Poland, Belgium, Hungary, Serbia, Finland, Ukraine, Switzerland, Canada, Turkey
Clinical Trials on Mesna
-
Lawson Health Research InstituteCanadian Institutes of Health Research (CIHR)Completed
-
Vanderbilt UniversityTerminatedImplant Capsular Contracture
-
Pharco PharmaceuticalsCompletedSchistosomiasis Mansoni | Schistosoma Hematobium InfectionEgypt
-
University of OsloOslo University Hospital; University of OxfordCompleted
-
Assiut UniversityUnknown
-
University of UlmCompletedChronic Renal Insufficiency | Serum Creatinine Concentration | Contrast Media ExpositionGermany
-
Mark DewhirstNational Cancer Institute (NCI)Completed
-
University of RochesterCompletedLymphoma | Multiple Myeloma | Myelofibrosis | Solid Tumors | Hematological Disease | Immune DeficienciesUnited States
-
Yonsei UniversityRecruitingProstatic NeoplasmKorea, Republic of